📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 23:09
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Manipal Health AGM: 10 Resolutions Passed, Upside Sharing Agreement Defeated with 61.99% Against
Manipal Health Enterprises Limited concluded its 16th AGM on September 29, 2026, where 10 of 11 proposed resolutions were approved by shareholders. Notably, Resolution 9 regarding an Upside Sharing Arrangement between Manipal Research & Management Services International and TPG SG Magazine Pte. Ltd. was defeated, receiving 61.99% votes against (6,68,85,785 votes against vs 4,10,16,249 in favour). Other key proposals passed, including Price Waterhouse Chartered Accountants LLP's appointment as statutory auditor (99.99% approval) and special governance rights under the Articles of Association for Temasek and MGHS Groups (94.45% approval).
Confidence: HIGH
What changedShareholders adopted audited FY26 financials, appointed PwC as statutory auditor, and granted board nomination rights to Temasek/MGHS, while blocking a proposed Upside Sharing Arrangement.
Why it mattersThe rejection of the related-party upside sharing arrangement demonstrates active institutional/public shareholder scrutiny over private equity/promoter arrangements, while broader operational governance continues smoothly.
Voting turnout on outstanding shares: 91.3663%Resolution 9 votes against: 61.9875%Resolution 10 (AoA amendment) approval: 94.4546%Total shareholders on record date: 175035
📅 Short termLimited market impact expected as core governance and auditor approvals went through normally, though clarity may be sought on the rejected upside sharing proposal.
📈 Long termApproval of governance and nomination rights codifies key investor roles (Temasek and MGHS) on the board.
⚠ Risk flags
- Shareholder pushback on related-party / bilateral upside sharing agreements
Key Highlights
10 out of 11 resolutions approved at the 16th AGM held on September 29, 2026
Resolution 9 (Upside Sharing Arrangement with TPG) rejected with 61.9875% votes cast against
PwC appointed as statutory auditor with 99.9999% votes in favour (1,20,18,09,921 votes)
Amendments to Articles of Association granting rights to Temasek and MGHS Groups passed with 94.4546% approval
Total voter turnout represented 91.3663% of outstanding shares (1,20,18,10,823 votes polled)
👀 What to Watch
Track subsequent company disclosures regarding the rejected Upside Sharing Arrangement and any restructuring of agreements involving TPG or promoter entities.
Manipal Hospitals Redeems ₹5,310 Crore NCDs Using IPO Proceeds
Manipal Health Enterprises Limited has fully redeemed outstanding listed Non-Convertible Debentures (NCDs) worth ₹5,310 crore issued by its subsidiary, Manipal Hospitals Private Limited, utilizing its IPO proceeds. The redemption covers principal, accrued interest, and early redemption costs in accordance with its July 31, 2026 prospectus objects. This debt reduction is aimed at significantly strengthening the balance sheet and lowering future interest burdens. In Q1 FY27, the company reported consolidated revenue growth of 38.1% year-on-year to ₹3,091 crore and an EBITDA of ₹749 crore.
Confidence: HIGH
What changedFully paid off ₹5,310 crore of subsidiary NCD debt using proceeds raised from the recent IPO.
Why it mattersDe-leverages the consolidated balance sheet substantially, cutting financing expenses and expanding operational cash flows for future healthcare capacity investments.
Redeemed NCD Nominal Value: ₹5,310 croreQ1 FY27 Revenue: ₹3,091 croreQ1 FY27 EBITDA: ₹749 croreTotal Bed Capacity: over 13,000 licensed beds
📅 Short termPositive sentiment driver as the company swiftly executes stated IPO debt-reduction commitments.
📈 Long termSignificantly strengthens solvency, lowers leverage ratios, and creates financial headroom to fund ongoing expansion across its hospital network.
Key Highlights
Full redemption of outstanding listed NCDs with nominal value of ₹5,310 crore
Funded via IPO proceeds in line with the prospectus dated July 31, 2026
Q1 FY27 revenue stood at ₹3,091 crore (up 38.1% YoY) with EBITDA at ₹749 crore (up 26.4% YoY)
Q1 FY27 PAT reported at ₹243 crore, with adjusted PAT reaching ₹332 crore
👀 What to Watch
Monitor upcoming quarterly filings to track the reduction in finance costs and the resultant expansion in net profit margins following this debt clearance.
Manipal Health Redeems Rs 5,310 Cr NCDs of Subsidiary Using IPO Proceeds
Manipal Health Enterprises Limited has fully redeemed outstanding listed non-convertible debentures (NCDs) worth Rs 5,310 crore issued by its wholly owned subsidiary, Manipal Hospitals Private Limited. The redemption, which includes accrued interest and early prepayment charges, was funded using the proceeds from its recent Initial Public Offering. This utilization aligns with the stated objects of the offer outlined in its Prospectus dated July 31, 2026. The full repayment significantly deleverages the consolidated balance sheet.
Confidence: HIGH
What changedUtilisation of IPO proceeds to complete the full prepayment and redemption of Rs 5,310 crore NCD debt.
Why it mattersA debt reduction of Rs 5,310 crore will substantially lower consolidated interest outgo, boosting profitability and strengthening the balance sheet.
NCD Redemption Nominal Value: Rs. 5,310 croresProspectus Date: July 31, 2026Quarterly Revenue (Jun 2026): Rs 1048.3 cr
📅 Short termPositive sentiment driver as the company swiftly deploys IPO funds towards planned deleveraging.
📈 Long termSubstantial reduction in interest burden positions the company for higher free cash flow generation and improved return ratios.
⚠ Risk flags
- Prepayment and early redemption costs incurred, though planned in IPO objects
Key Highlights
Full redemption of Rs 5,310 crore nominal value listed NCDs issued by subsidiary Manipal Hospitals Private Limited
Funded via relevant portion of proceeds raised through the company's Initial Public Offering
Redemption includes nominal value, accrued interest, and applicable early prepayment costs
Executed strictly as per the objects of the offer detailed in the Prospectus dated July 31, 2026
👀 What to Watch
Track the upcoming quarterly financial results to observe the reduction in finance costs and the resultant expansion in net profit margins.
Manipal Health Q1 Revenue Up 38% YoY to ₹3,091 Cr, Network EBITDA at ₹749 Cr
Manipal Health Enterprises released the transcript of its Q1 FY27 earnings call, reporting consolidated revenue of ₹3,091 crore, up over 38% YoY. Network EBITDA reached ₹749 crore (+26% YoY) with an operating margin of 24.2% (25% excluding Sahyadri Hospitals). Growth was driven by a 39% rise in inpatient volumes and 26% in OP volumes, with network occupancy at 65% and ALOS at 2.7 days. The company has expanded its network to over 13,000 beds, launched its 50th hospital in Bangalore, and maintains a low net debt-to-EBITDA ratio of 0.9x post-IPO.
Confidence: HIGH
What changedFiling of the official verbatim transcript of the inaugural Q1 FY27 analyst conference call detailing growth drivers, integration updates, and expansion strategy.
Why it mattersProvides granular operational clarity across ARPOB, ALOS, specialty revenue contributions (65% from Centres of Excellence), and capacity additions across key metro hubs.
Q1 Revenue: ₹3,091 croreNetwork EBITDA: ₹749 croreARPOB (ex-Sahyadri): ₹77,200 per dayAverage Occupancy: 65%Debt to EBITDA: 0.9 times
📅 Short termTranscript reinforces strong volume execution in Q1 and provides clarity on brownfield expansion timelines in major metros.
📈 Long termCapacity pipeline of 1,000-2,000 upcoming beds, low leverage (0.9x debt/EBITDA), and turnaround potential at Sahyadri provide strong structural growth visibility.
⚠ Risk flags
- Integration and margin dilution risks during the turnaround phase of acquired networks like Sahyadri
- Gestation losses and execution delays across upcoming greenfield projects (Raipur, Juhu, Wakad)
Key Highlights
Q1 revenue grew 38% YoY to ₹3,091 crore with Network EBITDA reaching ₹749 crore (24.2% margin)
ARPOB ex-Sahyadri rose 9% YoY to ₹77,200/day, with network occupancy improving by 290 bps to 65%
Sahyadri Hospitals delivered ₹332 crore in revenue and ₹58 crore EBITDA (17% margin vs 25% ex-Sahyadri)
Digital revenue contributed ₹710 crore, accounting for 23% of total revenue in Q1
Total network capacity stands above 13,000 beds following 103 brownfield beds in Nashik and a new 300-bed unit in Electronic City
👀 What to Watch
Track margin expansion at Sahyadri Hospitals toward the corporate average of 25%, alongside the operational ramp-up of newly added greenfield and brownfield capacities.
Manipal Health Recommends Price Waterhouse as Auditor, Updates Governance & Board Rights
Manipal Health Enterprises has approved the appointment of Price Waterhouse Chartered Accountants LLP as its statutory auditor for a 5-year tenure (FY27 to FY31), succeeding BSR & Co. LLP upon tenure completion. The Board also approved amendments to the Articles of Association granting Temasek Group right to nominate up to 3 directors and MGHS Group up to 2 directors, provided each holds at least 6% equity. Additionally, the Board noted an upside sharing payment between TPG and promoter entity MRMSI, subject to shareholder approval at the AGM scheduled for September 29, 2026.
Confidence: HIGH
What changedStatutory auditor transition to Price Waterhouse for 5 years and formalization of board nomination rights for Temasek and MGHS in the Articles of Association.
Why it mattersProvides institutional clarity on board seat allocations between major institutional investor Temasek and promoter entities while fulfilling mandatory statutory auditor rotation requirements.
Auditor appointment tenure: 5 consecutive years (FY2026-27 to FY2030-31)Temasek nomination shareholding threshold: at least 6% (up to 3 Directors)MGHS nomination shareholding threshold: at least 6% (up to 2 Directors)AGM date: September 29, 2026
📅 Short termRoutine governance and compliance event; resolutions will be placed before shareholders at the AGM on September 29, 2026.
📈 Long termSolidifies governance structure and board representation balance between key strategic shareholders and the promoter group.
⚠ Risk flags
- Shareholder approval required for the proposed AoA changes and the TPG-promoter upside sharing transaction under SEBI Listing Regulations.
Key Highlights
Appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term from the 16th AGM to 21st AGM.
AoA amendment enabling Temasek Group to nominate up to 3 Directors and 3 Executive Committee members subject to a minimum 6% holding.
AoA amendment enabling MGHS Group to nominate up to 2 Directors and 2 Executive Committee members subject to a minimum 6% holding.
Noted upside share amount payable by TPG to promoter group entity MRMSI under March 16, 2026 agreement, subject to Reg 26(6) shareholder approval.
16th Annual General Meeting scheduled for September 29, 2026.
👀 What to Watch
Track the upcoming AGM on September 29, 2026 for shareholder voting outcomes on the statutory auditor appointment, AoA amendments, and the upside sharing arrangement.
Manipal Hospitals Q1 FY27 Revenue Up 38.1% YoY to ₹3,091 Cr; Adjusted PAT at ₹332 Cr
Manipal Health Enterprises reported a 38.1% YoY increase in revenue from operations to ₹3,091 crore for Q1 FY27 in its first earnings report post-listing. EBITDA grew 26.4% YoY to ₹749 crore with a 24.2% margin (adjusted EBITDA up 29.7% YoY). Reported PAT stood at ₹243 crore, while PAT adjusted for ₹89 crore post-tax interest on Sahyadri acquisition NCDs rose 30.9% YoY to ₹332 crore. Network occupancy improved by 290 bps YoY to 65.0%, and ARPOB (excluding Sahyadri) grew 8.7% YoY to ₹77,200 per day.
Confidence: HIGH
What changedManipal Hospitals published its first quarterly results (Q1 FY27) since listing, delivering strong top-line and operating volume growth.
Why it mattersConfirms operational execution post-IPO across its 50-hospital pan-India network, with high-acuity specialty cases driving ARPOB and volume growth.
Revenue from operations (Q1 FY27): ₹3,091 croreEBITDA (Q1 FY27): ₹749 croreReported PAT (Q1 FY27): ₹243 croreAdjusted PAT (Q1 FY27): ₹332 croreBlended Occupancy Rate: 65.0%ARPOB (ex-Sahyadri): ₹77,200/day
📅 Short termMarket reaction will likely be positive due to robust operating metrics, with focus turning to management commentary in the earnings call.
📈 Long termIntegration of acquired assets like Sahyadri and growing high-acuity CONGO-R mix provide structural support for operational leverage over the medium-to-long term.
⚠ Risk flags
- High finance costs (₹293.3 crore in Q1 FY27) tied to acquisition debt
- Integration and execution risks related to ongoing brownfield and greenfield capacity additions
Key Highlights
Revenue from operations grew 38.1% YoY to ₹3,091 crore in Q1 FY27 compared to ₹2,238 crore in Q1 FY26.
EBITDA increased 26.4% YoY to ₹749 crore; adjusted EBITDA (ex-one-off) grew 29.7% YoY.
Adjusted PAT reached ₹332 crore (up 30.9% YoY), excluding ₹89 crore post-tax interest on Sahyadri NCD debt.
Occupancy expanded 290 bps YoY to 65.0%, with inpatient volumes up 38.8% YoY.
Sahyadri Hospitals contributed ₹332 crore in revenue (+12.8% YoY) and ₹58 crore in EBITDA (+18.7% YoY).
👀 What to Watch
Monitor commentary from the August 21, 2026 earnings conference call regarding debt reduction timelines and execution progress on Sahyadri integration synergies.
Manipal Hospitals Q1 FY27 Revenue Up 38.1% YoY to ₹3,091 Cr; EBITDA Up 26.4% to ₹749 Cr
In its maiden quarterly results post-listing, Manipal Health Enterprises reported a 38.1% YoY increase in consolidated revenue from operations to ₹3,091 crore for Q1 FY27. EBITDA grew 26.4% YoY to ₹749 crore, with adjusted EBITDA growing 29.7% YoY excluding a one-off gain in the base quarter. Reported PAT was ₹243 crore, while PAT adjusted for ₹89 crore post-tax interest on NCDs for the Sahyadri acquisition rose 30.9% YoY to ₹332 crore. Network occupancy improved by 290 bps YoY to 65.0%, supported by a 38.8% growth in inpatient volumes.
Confidence: HIGH
What changedManipal Hospitals released its first quarterly financial results and investor presentation after its August 5, 2026 stock market listing.
Why it mattersDemonstrates robust capacity absorption, strong 45% YoY growth in high-acuity CONGO-R specialties, and positive integration traction from the Sahyadri acquisition.
Revenue from operations (Q1 FY27): ₹3,091 crEBITDA (Q1 FY27): ₹749 crAdjusted PAT (Q1 FY27): ₹332 crNetwork Occupancy: 65.0%ARPOB (ex-Sahyadri): ₹77,200 / day
📅 Short termMarket sentiment is expected to react favorably to the strong top-line and operating metrics in the company's debut quarter as a listed entity.
📈 Long termWith over 13,400 licensed beds across 50 hospitals, continued clinical excellence and brownfield expansions position the platform well to capture rising healthcare demand.
⚠ Risk flags
- High finance costs (₹293.3 cr in Q1 FY27) associated with acquisition borrowings
- Integration risks for newly acquired facilities like Sahyadri Hospitals
Key Highlights
Revenue from operations grew 38.1% YoY to ₹3,091 crore in Q1 FY27
EBITDA increased 26.4% YoY to ₹749 crore; adjusted EBITDA up 29.7% YoY
Reported PAT stood at ₹243 crore; adjusted PAT rose 30.9% YoY to ₹332 crore (ex-Sahyadri acquisition debt interest)
ARPOB excluding Sahyadri increased 8.7% YoY to ₹77,200 per day
Consolidated network occupancy improved 290 bps YoY to 65.0%
👀 What to Watch
Track the earnings call scheduled for August 21, 2026, for management commentary on Sahyadri integration synergies, debt reduction post-IPO, and brownfield/greenfield bed addition timelines.
Manipal Health Appoints Price Waterhouse as Statutory Auditor for 5 Years; Updates AoA
Manipal Health Enterprises Limited's Board approved the appointment of M/s Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term from FY 2026-27 to FY 2030-31 (16th AGM to 21st AGM), replacing M/s BSR & Co. LLP upon tenure completion. The Board also approved amendments to the Articles of Association (AoA) granting Temasek Group (up to 3 nominees) and MGHS Group (up to 2 nominees) board and executive committee nomination rights subject to maintaining at least 6% equity shareholding. Additionally, the 16th AGM is scheduled for September 29, 2026, where shareholder approval will also be sought for an upside sharing agreement between TPG and promoter entity MRMSI under SEBI LODR Regulation 26(6).
Confidence: HIGH
What changedMandatory rotation of statutory auditors to Price Waterhouse for 5 years and formalization of board nomination thresholds (6% minimum holding) for Temasek and MGHS Groups in the AoA.
Why it mattersEnsures regulatory compliance regarding auditor rotation and codifies major shareholder governance rights and board representation thresholds.
Auditor tenure: 5 consecutive yearsTemasek minimum holding threshold for 3 nominees: 6%MGHS Group minimum holding threshold for 2 nominees: 6%AGM date: September 29, 2026
📅 Short termNeutral procedural impact as the auditor change is due to tenure completion and director re-appointments are routine rotations.
📈 Long termInstitutionalizes long-term governance and board structure between key institutional stakeholders (Temasek) and promoters (MGHS Group).
⚠ Risk flags
- Shareholder approval required for promoter upside sharing arrangement under SEBI Listing Regulations
Key Highlights
Appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for 5 consecutive years (FY 2026-27 to FY 2030-31)
AoA amendment grants Temasek Group right to nominate up to 3 directors while holding at least 6% equity
MGHS Group granted right to nominate up to 2 directors while holding at least 6% equity
16th Annual General Meeting scheduled for September 29, 2026 via video conferencing
Noted upside share payment from TPG to promoter entity MRMSI per March 16, 2026 agreement, subject to shareholder approval
👀 What to Watch
Track voting outcomes of the upcoming 16th AGM on September 29, 2026, specifically regarding the AoA amendments and the Regulation 26(6) approval for the promoter upside sharing arrangement.
Manipal Health Approves Q1 Results, Appoints PW as Auditor & Proposes Governance Changes
Manipal Health Enterprises Limited approved its unaudited financial results for the quarter ended June 30, 2026, with an unmodified review report. The Board recommended the appointment of M/s Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term (FY27 to FY31) replacing BSR & Co. LLP. Additionally, the Board proposed an amendment to the Articles of Association allowing Temasek Group to nominate up to 3 directors and MGHS Group up to 2 directors, provided each holds at least 6% equity. The 16th Annual General Meeting is scheduled for September 29, 2026.
Confidence: HIGH
What changedThe Board approved Q1 FY27 results, proposed new statutory auditors (PW) for 5 years, and structured long-term board nomination rights for Temasek and MGHS groups.
Why it mattersFormalizes institutional governance representation between major shareholders (Temasek and MGHS Group) and completes statutory auditor rotation.
Auditor appointment term: 5 consecutive yearsTemasek board nomination threshold: at least 6%MGHS Group board nomination threshold: at least 6%AGM Date: September 29, 2026
📅 Short termRoutine corporate governance intimation; market attention will focus on underlying quarterly operational performance figures.
📈 Long termSolidifies institutional board representation and governance framework aligned with major private equity and promoter ownership.
⚠ Risk flags
- Shareholder approval required for AoA amendments and related upside sharing transaction under Reg 26(6).
Key Highlights
Approved standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
Appointed M/s Price Waterhouse Chartered Accountants LLP for a 5-year term from the 16th AGM (2026) to the 21st AGM (2031).
Proposed AoA amendment granting Temasek Group up to 3 board seats and MGHS Group up to 2 seats, subject to maintaining a minimum 6% equity stake.
Noted upside sharing arrangement between TPG and MRMSI dated March 16, 2026, requiring shareholder approval under SEBI Reg 26(6).
Scheduled the 16th Annual General Meeting on Tuesday, September 29, 2026.
👀 What to Watch
Track voting outcomes at the upcoming 16th AGM on September 29, 2026, particularly regarding the AoA governance amendments and statutory auditor appointment.
Manipal Health to Acquire Kinder Women's Hospital in Bengaluru for ₹130 Crore
Manipal Health Enterprises Limited has signed a Business Transfer Agreement (BTA) to acquire the operations and assets of Kinder Women's Hospital in Whitefield, Bengaluru, for a cash consideration of ₹130 Crore. The hospital, commissioned in 2022, adds 100 beds to Manipal's existing presence in the Whitefield micro-market. The acquisition will expand Manipal's total footprint to over 13,500 licensed beds across 51 hospitals nationwide. The transaction does not involve share acquisition and is expected to close within 90 days subject to regulatory and customary approvals.
Confidence: HIGH
What changedManipal Health signed a BTA to acquire 100% operations and assets of 100-bed Kinder Women's Hospital for ₹130 Cr.
Why it mattersStrengthens micro-market dominance in Whitefield, Bengaluru with an operational asset, avoiding greenfield development gestation periods.
Deal value: INR 130 CroresBed capacity added: 100 bedsTotal network licensed beds: over 13,500 licensed bedsTotal hospital count: 51 hospitalsTransaction closing timeline: within 90 days
📅 Short termTransaction progresses towards closing over the next 90 days pending regulatory clearances and fulfillment of conditions precedent.
📈 Long termEnhances regional cluster synergies and patient capture in Bengaluru's Whitefield area, aiding overall operational leverage.
⚠ Risk flags
- Subject to fulfillment of conditions precedent and statutory approvals within 90 days
- Integration and operational ramp-up risk
Key Highlights
Signed Business Transfer Agreement to acquire Kinder Women's Hospital for ₹130 Crores cash consideration.
Adds 100 beds to network, expanding Manipal's pan-India capacity to over 13,500 licensed beds across 51 hospitals.
Acquired hospital was recently commissioned in 2022 in the Whitefield (Doddanekundi) micro-market in Bengaluru.
Transaction expected to close within 90 days, subject to statutory approvals and conditions precedent.
👀 What to Watch
Track the formal closing of the transaction within the 90-day window and management commentary on occupancy and EBITDA margins for the acquired asset.
Manipal Health to Acquire 100-Bed Kinder Hospital in Bengaluru for ₹130 Cr
Manipal Health Enterprises Limited has entered into a Business Transfer Agreement to acquire the entire operations and assets of Kinder Women's Hospital and Fertility Centre in Bengaluru from Kindorama Healthcare Private Limited. The transaction is an all-cash asset acquisition valued at ₹130 crore. The target hospital operates a 100-bed facility and reported a turnover of ₹20.75 crore for the financial year ended March 31, 2026. The acquisition is slated for completion within 90 days, subject to statutory and customary approvals.
Confidence: HIGH
What changedSigned a BTA to buy the assets and operations of the 100-bed Kinder Women's Hospital and Fertility Centre in Bengaluru for ₹130 crore.
Why it mattersExpands bed capacity in the key Bengaluru micro-market and strengthens Manipal's presence in specialized women and fertility healthcare services.
Cost of acquisition: INR 130,00,00,000Target FY26 revenue: INR 20,74,95,999.28Capacity: 100 bedsCompletion timeline: Within 90 days
📅 Short termFocus remains on satisfying conditions precedent and obtaining ownership-transfer regulatory approvals over the next 90 days.
📈 Long termStrengthens network density in Bengaluru with potential operational synergies and ramp-up in utilization across specialized healthcare streams.
⚠ Risk flags
- Execution and integration risk post-acquisition
- Pending statutory and customary approvals for ownership transfer
Key Highlights
Acquiring complete business operations and assets of Kinder Hospital for an all-cash consideration of ₹130 crore.
Adds a 100-bed hospital capacity situated in Doddanekundi Industrial Area, Bengaluru.
Target hospital recorded FY26 revenue from operations of ₹20.75 crore.
Target facility was commissioned in 2022; transaction expected to close within 90 days.
👀 What to Watch
Track the closing of the transaction within the 90-day window and subsequent operational integration into Manipal's Bengaluru hospital cluster.
